Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
|Videos|November 14, 2016
HER2+ Early-Stage Breast Cancer with Ruth O'Regan, MD Case 1
HER2+ Early-Stage Breast Cancer with Ruth O'Regan, MD
Advertisement
Case Scenario 1:
- This is a post-menopausal 58-year-old female in whom a mass was discovered in her right breast during her annual mammography.
- Her gynecologist referred her to a breast surgeon; results of her biopsy revealed 3 cm ductal carcinoma
- Pathology shows: ER & PR–, HER2 IHC 3+
- Clinical staging; T2aN1M0
- Her surgeon discussed the patient’s case at the Breast Tumor Board and it was suggested that the patient be referred to a medical oncologist for consideration of HER2-targeted neoadjuvant therapy.
- The surgeon shared his opinion with the patient who agreed to go to the medical oncologist to discuss her options.
Advertisement
Related to this article
Claire K. Mulvey, MD, explains how patient-reported outcomes and QOL assessments reveal NEN symptom burden and help guide treatment.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Liver transplant led to durable survival in unresectable NET liver metastases; tumor burden predicted outcomes, and recurrence was common but treatable.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Erica S. Alexander, MD, highlights endovascular approaches to venous occlusion, including stenting and thrombolysis, for select patients with NETs.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high-grade neuroendocrine cancers.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5